SCHEMBL5544664

SCHEMBL5544664

CC(O)(CN1CCN(N=Cc2cc3cc(C(F)(F)F)ccc3o2)CC1)Cn1cc([N+](=O)[O-])nc1Cl

nearest known ligand 0.33

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 6/20 0.33
GAA P10253 2/20 0.33
MAOA P21397 1/20 0.32
MAPK1 P28482 3/20 0.32
TDP1 Q9NUW8 2/20 0.32
L3MBTL1 Q9Y468 2/20 0.32
CYP1A2 P05177 2/20 0.32
CYP2D6 P10635 2/20 0.32
CYP2C19 P33261 2/20 0.32
POLB P06746 2/20 0.32
MEN1 O00255 1/20 0.32
KMT2A Q03164 1/20 0.32
NPSR1 Q6W5P4 1/20 0.32
ALDH1A1 P00352 1/20 0.32
RAB9A P51151 1/20 0.32
HRH3 Q9Y5N1 3/20 0.32
LMNA P02545 1/20 0.31
SMN1; SMN2 Q16637 1/20 0.31
PIM1 P11309 1/20 0.31
PIM2 Q9P1W9 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5544661 1.00 MAPT (0.33) MAPTGAAMAOAMAPK1TDP1
SCHEMBL5544660 1.00 MAPT (0.33) MAPTGAAMAOAMAPK1TDP1
SCHEMBL5540766 0.91 ALDH1A1 (0.37) MAPTGAAMAPK1TDP1L3MBTL1
SCHEMBL5540758 0.91 ALDH1A1 (0.37) MAPTGAAMAPK1TDP1L3MBTL1
SCHEMBL5540763 0.91 ALDH1A1 (0.37) MAPTGAAMAPK1TDP1L3MBTL1
SCHEMBL5543337 0.85 MAPT (0.45) MAPTGAAMAOAMAPK1TDP1
SCHEMBL5543344 0.85 MAPT (0.45) MAPTGAAMAOAMAPK1TDP1
SCHEMBL5543334 0.85 MAPT (0.45) MAPTGAAMAOAMAPK1TDP1
SCHEMBL5541743 0.77 KCNH2 (0.39) MAPTGAAMAPK1L3MBTL1POLB
SCHEMBL5541725 0.77 KCNH2 (0.39) MAPTGAAMAPK1L3MBTL1POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1555267-B1 2,3-DIHYDRO-6-NITROIMIDAZO[2,1-b]OXAZOLES OTSUKA PHARMA CO LTD (JP) 2013-01-16 EP disclosed
US-7262212-B2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2007-08-28 US disclosed
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2006-05-04 US disclosed
EP-1555267-A1 2,3-DIHYDRO-6-NITROIMIDAZO 2,1-b OXAZOLES OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2005-07-20 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles NR2C2, NR4A3, NR4A2 MAPT 4117/4885GAA 4165/4885MAOA 2885/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.